TY - JOUR
T1 - Protein kinase C and amyloid precursor protein processing in skin fibroblasts from sporadic and familial Alzheimer's disease cases
AU - Vestling, Monika
AU - Cedazo-Mínguez, Ángel
AU - Adem, Abdu
AU - Wiehager, Birgitta
AU - Racchi, Marco
AU - Lannfelt, Lars
AU - Cowburn, Richard F.
N1 - Funding Information:
We thank Dr. Nikolaus Venizelos for establishing the cell lines from all the familial individuals. This study was supported by research grants from The Swedish Medical Research Council (K97-19X-12244-01A), the European Union Biomed-2 concerted action (contract number bmh4-ct-96-0162), Axel och Margareta Ax:son Johnsons Foundation, Stiftelsen för Gamla Tjänarinnor, Loo and Hans Osterman’s Foundation, Karolinska Institute research fund, Stiftelsen Sigurd and Elsa Goljes Minne, Eva and Oscar Ahrén Research Foundation, Stockholm.
PY - 1999/3/30
Y1 - 1999/3/30
N2 - Non-amyloidogenic α-secretase processing of amyloid precursor protein (APP) is stimulated by protein kinase C (PKC). Levels and activity of PKC are decreased in sporadic Alzheimer's disease skin fibroblasts. We investigated whether alterations in PKC and PKC-mediated APP processing occur also in fibroblasts established from individuals with familial Alzheimer's disease APP KM670/671NL, PS1 M146V and H163Y mutations. These pathogenic mutations are known to alter APP metabolism to increase Aβ. PKC activities, but not levels, were decreased by 50% in soluble fractions from sporadic Alzheimer's disease cases. In contrast, familial Alzheimer's disease fibroblasts showed no significant changes in PKC enzyme activity. Fibroblasts bearing the APP KM670/671NL mutation showed no significant differences in either PKC levels or PKC-mediated soluble APP (APPs) secretion, compared to controls. Fibroblasts bearing PS1 M146V and H163Y mutations showed a 30% increase in soluble PKC levels and a 40% decrease in PKC-mediated APPs secretion. These results indicate that PKC deficits are unlikely to contribute to increased Aβ seen with APP and PS1 mutations, and also that PS1 mutations decrease α-secretase derived APPs production independently of altered PKC activity. Copyright (C) 1999 Elsevier Science B.V.
AB - Non-amyloidogenic α-secretase processing of amyloid precursor protein (APP) is stimulated by protein kinase C (PKC). Levels and activity of PKC are decreased in sporadic Alzheimer's disease skin fibroblasts. We investigated whether alterations in PKC and PKC-mediated APP processing occur also in fibroblasts established from individuals with familial Alzheimer's disease APP KM670/671NL, PS1 M146V and H163Y mutations. These pathogenic mutations are known to alter APP metabolism to increase Aβ. PKC activities, but not levels, were decreased by 50% in soluble fractions from sporadic Alzheimer's disease cases. In contrast, familial Alzheimer's disease fibroblasts showed no significant changes in PKC enzyme activity. Fibroblasts bearing the APP KM670/671NL mutation showed no significant differences in either PKC levels or PKC-mediated soluble APP (APPs) secretion, compared to controls. Fibroblasts bearing PS1 M146V and H163Y mutations showed a 30% increase in soluble PKC levels and a 40% decrease in PKC-mediated APPs secretion. These results indicate that PKC deficits are unlikely to contribute to increased Aβ seen with APP and PS1 mutations, and also that PS1 mutations decrease α-secretase derived APPs production independently of altered PKC activity. Copyright (C) 1999 Elsevier Science B.V.
KW - Alzheimer's disease
KW - Amyloid precursor protein
KW - Fibroblast
KW - Presenilin
KW - Protein kinase C
UR - http://www.scopus.com/inward/record.url?scp=0344507324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344507324&partnerID=8YFLogxK
U2 - 10.1016/S0925-4439(99)00003-4
DO - 10.1016/S0925-4439(99)00003-4
M3 - Article
C2 - 10101252
AN - SCOPUS:0344507324
SN - 0925-4439
VL - 1453
SP - 341
EP - 350
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 3
ER -